Stoke Therapeutics, Inc.
STOK
$26.10
-$3.94-13.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,218.82% | 2,333.50% | 316.30% | 81.06% | 71.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,218.82% | 2,333.50% | 316.30% | 81.06% | 71.38% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1,218.82% | 2,333.50% | 316.30% | 81.06% | 71.38% |
| SG&A Expenses | 25.63% | 28.78% | 18.08% | 16.12% | 10.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.07% | 20.88% | 11.63% | 10.23% | 7.08% |
| Operating Income | 135.17% | 132.28% | 11.68% | -4.40% | -2.01% |
| Income Before Tax | 151.91% | 147.50% | 15.01% | -1.99% | 1.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 150.68% | 146.32% | 15.01% | -1.99% | 1.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 150.68% | 146.32% | 15.01% | -1.99% | 1.33% |
| EBIT | 135.17% | 132.28% | 11.68% | -4.40% | -2.01% |
| EBITDA | 137.69% | 134.76% | 11.67% | -4.66% | -1.90% |
| EPS Basic | 140.98% | 134.62% | 29.18% | 13.54% | 13.86% |
| Normalized Basic EPS | 141.99% | 135.53% | 29.18% | 13.54% | 13.86% |
| EPS Diluted | 138.66% | 132.52% | 29.18% | 13.54% | 13.86% |
| Normalized Diluted EPS | 139.66% | 133.42% | 29.18% | 13.54% | 13.86% |
| Average Basic Shares Outstanding | 20.05% | 26.35% | 22.41% | 19.30% | 15.50% |
| Average Diluted Shares Outstanding | 20.86% | 27.20% | 22.41% | 19.30% | 15.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |